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INTRODUCTION 
Articular cartilage is a highly specialized tissue, characterized by unique biomechanical 
properties and, on the other hand, a poor regenerative potential [1,2]. As a consequence, when 
a traumatic lesion or a non-traumatic disease such as osteochondritis dissecans occurs, the 
defect is filled with a fibrous tissue which is not capable to withstand the high compressive 
and shear forces acting in the joint, often leading to the development of early osteoarthritis 
[1]. An established surgical technique for the repair of osteochondral (OC) defects (i.e., 
mosaicplasty) involves transplantation of autologous OC plugs consisting of an articular 
cartilage layer and the underlying subchondral bone [3,4]. Despite the promising results 
reported, the use of autologous OC grafts suffers from several limitations, namely (i) amount 
of material available, (ii) donor site morbidity, and (iii) difficult graft/injured site matching. In 
vitro fabrication of OC composites of predefined size and shape starting from appropriate 
scaffolds, possibly combined with autologous cells, has the potential to overcome these limits 
[5]. 
To date, many tissue engineering approaches have been reported in literature to engineer 
OC grafts, both scaffold-free [6-8] or scaffold-based [9-12] for the chondral layer and cell-
free [12-14] or cell-seeded [10,11,15] for the bony layer. Also biphasic OC scaffolds have 
been proposed [15-17].  
The clinical translation of such strategies however is limited by the fact that (i) animal 
cells are often used instead of human cells [6,9]; (ii) the size of the graft is too small to be 
clinically relevant [6]; and (iii) the biomaterials used are not currently implanted in human 
patients. Moreover, the functionality of an engineered OC graft should be supported by (i) an 
efficient integration between the cartilage and bony layers, in order to withstand the shear 
forces acting in the joint, and at the same time (ii) a satisfactory maturation of the chondral 
layer, in order to allow partial loading and thus reduce post-operative immobilization. A 
chemical or physical bonding of the biomaterials would not necessarily guarantee a long 
 2 
lasting integration of the chondral and bony layers, especially if the degradation of the 
materials is not accompanied by an efficient neo-formation of extracellular matrix at the 
interface. Instead, a “biological bonding” between the two layers, namely their integration 
through the extracellular matrix synthesized by cultured cells, would provide an actively and 
durably interconnected interface even following the resorption/degradation of the 
biomaterials. 
In this study, we aimed at developing and validating a method to engineer OC constructs 
based on the principle of biological bonding, and  using clinically relevant cells and 
biomaterials. In particular, our strategy consisted in coupling a human adult chondrocytes 
(HAC)-seeded collagen type I/III matrix (Chondro-Gide®, Geistlich Pharma AG, 
Switzerland) with a cell-free devitalized bovine trabecular bone cylinder (Tutobone®, Tutogen 
Medical GmbH, Neuenkirchen am Brand, Germany) using fibrin glue (Tisseel®, Baxter 
Healthcare, Newbury, UK). Chondro-Gide®, Tutobone® and Tisseel® are extensively used 
biomaterials in clinical practice for cartilage repair, bone reconstruction and wound healing, 
respectively. 
We opted for a cell-free bony layer since osteoprogenitor cells, abundantly present in the 
bleeding subchondral bone during implantation, are expected to colonize the scaffold and 
efficiently promote new bone formation [12,16,18]. We then developed a mechanical test and 
used it to address whether pre-culture time of chondrocyte-seeded matrices before 
combination with bony layers modulates the extent of integration between the two layers of 
resulting OC constructs. Finally, we investigated the quality of the chondral layer and whether 






MATERIALS AND METHODS 
Cartilage biopsies, articular chondrocytes isolation and expansion 
Cartilage tissues without signs of osteoarthritis were collected from the femoral condyles of 5 
cadavers (3 males and 2 females; mean age: 57 years; range 31-81 years) without 
macroscopic sign of arthritis, following informed consent by relatives and in accordance with 
the Local Ethical Committee. Cartilage tissues were weighed, minced into small pieces and 
digested with 0.15% type II collagenase (10 mL solution/g tissue) for 22 hours. The isolated 
human articular chondrocytes (HAC) were expanded for two passages with Dulbecco’s 
Eagle’s Medium (DMEM) containing 4.5 mg/mL D-glucose, 0.1 mM nonessential amino 
acids, 1 mM sodium pyruvate, 100 mM HEPES buffer, 100 U/mL penicillin, 100 µg/mL 
streptomycin and 0.29 mg/mL L-glutamate and supplemented with 10% of foetal bovine 
serum (complete medium-CM), 1 ng/mL of Transforming Growth Factor β1 (TGFβ-1), and 5 
ng/mL of Fibroblast Growth Factor 2 (FGF-2) (all from R&D Systems), as previously 
described [19].  
Generation of osteochondral samples 
Collagen type I/III matrices (Chondro-Gide®, Geistlich Pharma AG), cored out in the shape 
of discs (11 mm diameter), were used as scaffolds for the chondral layer. The bony layer 
consisted of devitalized bovine cancellous bone cylinders (11 mm diameter, 10 mm thickness) 
(Tutobone®, Tutogen Medical GmbH). In Group 1, expanded HAC were detached from 
culture flasks and suspended in a 40 mg/ml fibrinogen solution (Tisseel®, Baxter). 
Fibrinogen-embedded HAC were then loaded statically on the matrices, which were 
previously placed at the bottom of the wells of a custom-shaped silicon mould, at a density of 
12x106 cells / 50μl fibrinogen solution (Fig. 1A). The bony cylinders, pre-wetted in 8U/ml 
thrombin solution (Tisseel®, Baxter), were placed on the cell-seeded matrix using a gentle 
finger pressure. After 20 minutes of polymerization, the combined constructs were extracted 
from the mould, transferred to culture flasks and cultured in CM supplemented with 0.1 mM 
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ascorbic acid (Sigma), 10 µg/mL Insulin (Actrapid®, Novo Nordisk) and 10 ng/mL 
Transforming Growth Factor-β3 (R&D Systems) (Chondrogenic medium) in a humidified 
37°C/5% CO2 incubator. For Group 2 and Group 3 constructs, matrices were statically loaded 
with cells and combined with the bony scaffolds after being pre-cultured for 3 or 14 days in 
Chondrogenic medium, using fibrin glue as described above, but without cells in the 
fibrinogen solution. Constructs were cultured up to 5 weeks, with media changes twice a 
week.  
Development of a peel-off test for mechanical integration 
A peel-off test was developed to allow for precise measurement of the integration force 
between biphasic tissue-engineered constructs. The peel-off test was based on the American 
Society for Testing and Materials (ASTM) International (West Conshohocken, Pennsylvania, 
USA) test standard D 3330, designed for evaluating peel-off strength of thin adhesive films 
[20]. In contrast to a T peel test described in the literature [21,22], allowing to peel apart two 
layers of articular cartilage, the peel-off test developed here was designed to detach a 
cartilaginous layer from the underlying bone-replacement material. The peel-off test was 
developed and performed on a small-scale mechanical testing machine (MTS Synergie 100, 
MTS Systems, Inc. Eden Prairie, Minnesota, USA) equipped with a 2 N load cell. The bottom 
surface of the bony layer of an OC construct was attached to a glass plate with cyanoacrylate 
glue and the plate was secured to the steel platen of the testing machine. The edge of the 
chondral layer was grasped with a small surgical clamp attached to the crosshead of the 
testing machine (Fig. 2A). The crosshead was raised at 1 mm/s, and force and displacement 
were recorded until full detachment of the chondral layer occurred. Parameters assessed were 
maximum peel off force, and total peel energy, normalized to the interfacial areas of the 
samples.  
Histological and immunohistochemical analyses 
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Generated constructs were cut in half top-to-bottom, rinsed with PBS, fixed in 4% formalin 
and embedded in methylmetacrylate for histological analysis (Safranin-O for sulfated 
glycosaminoglycans – GAG –) or in paraffin for immunohistochemical examination. Sections 
of 7 µm thickness were processed for immunohistochemistry using antibodies anti type II 
collagen (CII) (II-II6B3, Hybridoma Bank, University of Iowa, USA) or type I collagen (CI) 
(Quartett Immunodiagnostika und Biotechnologie GmbH, Berlin, Germany), as previously 
described [23]. 
Biochemical Analyses 
Chondral and bony layers, delaminated during peel-off tests of OC constructs, as well as 
chondral-only controls, were digested for 15 hours at 56°C with protease K (1 mL for the 
chondral layer and 2 mL for the bony layer of 1 mg/mL protease K in 50 mM Tris with 1mM 
EDTA, 1 mM iodoacetamide and 10 µg/mL pepstatin-A, respectively). GAG amounts were 
measured spectrophotometrically after reaction with dimethylmethylene blue, with 
chondroitin sulfate as a standard. DNA was measured spectrofluorometrically using the 
CyQuant cell proliferation assay Kit (Molecular Probes, Eugene, OR), with calf thymus DNA 
as a standard.  
Real-Time quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)  
Total RNA was extracted from chondral and bony layers delaminated during the peel-off 
tests, as well as from chondral control samples (Fig. 1), using Trizol (Life Technologies, 
Basel, Switzerland) and the standard single-step acid-phenol guanidinium method. Samples 
were first sonicated for 1 min while in Trizol. RNA was treated with DNAseI using the DNA-
freeTM Kit (Ambion, USA) and quantified spectrofluorimetrically. cDNA was generated 
from 3 mg of RNA by using 500 mg/mL random hexamers (Catalys AG, CH) and 1 mL of 50 
U/mL StratascriptTM reverse transcriptase (Stratagene, NL), in the presence of dNTPs. PCR 
reactions were performed and monitored using the ABI Prism 7700 Sequence Detection 
System (Perkin-Elmer/Applied Biosystems, Rotkreuz, Switzerland). Cycle temperatures and 
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times as well as primers and probes used for the reference gene (GAPDH) and the genes of 
interest (collagen types I, II, X, and Bone sialoprotein – BSP –), were as previously described 
[19,24]. For each cDNA sample, the threshold cycle (Ct) value of GAPDH was subtracted 
from the Ct value of the target gene, to derive ∆Ct. The level of expression of the genes of 
interest was calculated as 2∆Ct.  
Statistical analysis 
For each analysis, at least triplicate pellets for each condition and donor were assessed. 
Statistical evaluation was performed using SPSS software version 7.5 software (SPSS, Sigma 
Stat). Values are presented as mean ± standard deviation (SD). Differences between groups 
were assessed by Mann-Whitney test and considered statistically significant when P values 
were lower than 0.05. 
 
RESULTS  
Validation of peel-off tests for mechanical integration 
Using cell-free OC constructs, we first tested two geometrical configurations, which based on 
the angle between the OC surface and the applied force are referred to as 90° peel-off or 180° 
peel-off (Fig. 2A). Both 90° peel-off and 180° peel-off were successfully implemented and 
gave repeatable results. Values measured with 90° peel-off were significantly higher than 
those measured with 180° peel-off (0.085 N ± 0.01 N and 0.065 N ± 0.01 N respectively; 
p<0.05) (Fig. 2B). The 90° peel-off configuration was used for successive experiments due to 
easier handling during the test.  
In order to determine whether this method would allow to quantify the integration derived 
from the matrix deposited at the osteochondral interface, we assessed both cell-free constructs 
and cell-based constructs cultured for 2 or 4 weeks in Chondrogenic medium (Fig. 2C). For 
this experiment, HAC from two different donors were used. Histological assessment of 
constructs confirmed the presence of cartilaginous matrix at the osteochondral interface, with 
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the most intense staining for GAG in constructs cultured for 4 weeks in Chondrogenic 
medium (data not shown). The baseline peel-off force of cell-free constructs averaged 0.08 N 
± 0.01 and progressively increased for constructs generated with cell-seeded matrices over the 
two culture time points (0.25 N ± 0.01 and 0.57 N ± 0.11 respectively). These results indicate 
that the test was capable to quantify the extent of integration between the two layers, upon 
matrix deposition at the interface (Fig. 2C).  
Modulation of the functionality of OC graft by preculturing the chondral layer 
Macroscopic examination 
The technique to generate the OC grafts demonstrated to be easy to perform and gave 
reproducible results in terms of shape of the grafts. The cartilaginous layer was glossy and 
resilient when probed with a pair of forceps. Macroscopic observation revealed some areas of 
discontinuity at the cartilage/bony interface in samples of Group 3, probably due to a certain 
irregularity in the shape of the generated constructs that did not allow for precise shape 
matching with the upper surface of the bony scaffold. In contrast, OC samples of Group 1 and 
2 appeared more regular (Fig. 3A).  
Histological and Immunohistochemical analyses 
Group 1 constructs contained a faintly Safranin-O stained extracellular matrix (ECM) mainly 
confined within the cartilage/bony interface. Group 2 constructs, instead, contained 
cartilaginous matrix intensely stained for GAG, comparable to that of chondral-only controls, 
which extended also to the cartilage/bony interface. Group 3 constructs displayed a faintly 
stained cartilaginous matrix, exclusively confined to the chondral layer, and including cells 
with picnotic-necrotic appearance (Fig. 3B). 
Immunohistochemical analysis indicated that the ECM was stained for type II collagen only 
in the cartilage layers of Group 2 constructs, although less intensely then control samples 
(Fig. 3C). In contrast, type I collagen was negative in all the constructs (data not shown).  
Integration tests 
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The peel-off test indicated that in Group 1 and Group 2 integration forces were significantly 
higher than in Group 3 constructs (up to 2.5- and 3.2-fold respectively for peak force and total 
energy of integration) (Fig. 4). Interestingly, peak force of Group 3 constructs was similar to 
that of cell-free constructs, suggesting that prolonged pre-culture did not result in a biological 
bonding between the two layers of the graft.  
Biochemical analysis 
DNA content of chondral layers from Group 2 and 3 were statistically significantly higher 
(3.8- and 2.2-fold respectively) that those from Group 1. Conversely, DNA contents in the 
bony layers of Group 1 were significantly higher than those of Group 2 and 3 (up to 2.1-fold) 
(Fig. 5A). These results suggest that in Group 1 constructs cells infiltrated more extensively 
the pores of the bony scaffold, while they remained more confined within the cartilage layers 
of the precultured constructs (Group 2 and 3). Consistent with the histological staining 
intensity and pattern, GAG amounts accumulated in the chondral layer of Group 2 constructs 
were remarkably and significantly higher than those measured in the chondral layers of Group 
1 and 3 constructs (up to 5.9-fold), whereas GAG amounts accumulated in the bony layers of 
Group 1 constructs were significantly higher that those measured in the bony layers of Group 
2 and 3 constructs (up to 2-fold) (Fig. 5A). The ratio of GAG/DNA, used as the quality index 
for the chondral layers [19] indicated that chondral tissues from the Group 2 constructs 
contained significantly higher contents of GAG as compared to those from Group 1 or 3 
constructs (2.0- and 3.2-fold respectively) and approached levels measured in chondral-only 
control constructs (Fig. 5B).   
Gene expression 
Chondral and bony layers from Group 2 constructs were assessed via RT-PCR to define the 
stage of differentiation of cells located in the Chondro-Gide® matrices or in the Tutobone® 
blocks. The expression of type I and type X collagen in the cartilage layers was similar to that 
of bony layers and of control chondral constructs. In contrast, type II collagen and BSP 
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expression were differentially regulated by the substrates used. In particular, type II collagen 
in the chondral layer was 73.1-fold higher than in the bony layer and, conversely, BSP in the 
bony layer was 11.1-fold higher than in the chondral layer (Fig. 6). These results suggest that 
HAC in the bony layers were less capable to re-differentiate into the chondrogenic lineage 
and appeared to acquire a more osteogenic phenotype.   
Effect of the bony scaffold on cartilaginous tissue development 
We have observed that the ECM deposited by HAC proximally to the trabeculae of the 
Tutobone® was faintly stained for GAG and type II collagen, while that produced by HAC on 
Chondro-Gide® was more strongly stained for the same cartilaginous macromolecules (Fig. 
3B,C). We thus performed an experiment aimed at assessing whether components released by 
Tutobone® may have caused the observed reduced HAC chondrogenesis. Cell-seeded matrices 
were cultured in the same wells together with Tutobone® blocks (co-culture Group) or alone 
(control Group) in Chondrogenic medium for 5 weeks (Fig. 1B). The resulting cartilaginous 
tissues were stained for GAG and type II collagen with comparable intensity (Fig. 7A, 7B). 
Biochemical analysis demonstrated that co-culture and control cartilaginous tissues contained 
similar amounts of DNA and GAG (Fig. 7C). These results suggest that the observed reduced 
chondrogenesis of HAC proximal to the bony layer is not caused by a release of chemicals 
from the Tutobone®, but probably by a limited exchange of nutrients, caused by the presence 
of an adjacent material. 
 
DISCUSSION  
In this study we succeeded in engineering in vitro functional osteochondral (OC) composites, 
where the chondral layer was efficiently developed and biologically integrated with a bony 
substrate through the extracellular matrix produced by human articular chondrocytes (HAC). 
In particular, in our experimental setting, which was based on clinically compliant cells and 
biomaterials, we demonstrated that 3 days of separate pre-culture of the chondral layer prior 
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to its fusion with the bony layer yielded a superior performance as compared to no pre-culture 
or 14 days pre-culture.  
Since delamination of the engineered cartilage has been recognized as one of the most 
frequent complications of ACI [25], integration between the two layers of an OC construct is 
a key issue in engineering composite grafts [5,9,26]. The potential drawback of a strategy 
relying on the use of two separate and not monolithic scaffolds for the generation of OC 
constructs must be compensated by an efficient integration between the two layers. An 
innovative approach to the problem of tissue bonding has been reported by Wang et al. using 
the biopolymer chondroitin sulphate as a biochemical glue [27]. Instead, our cell-based 
strategy relies upon the temporary adhesion provided by fibrin glue and on the cartilaginous 
extracellular matrix synthesized by HAC, which is expected to be further consolidated over 
time following implantation.  
In order to assess the integration strength between the chondral/bony layers, we developed a 
“peel-off test” which, unlike previously proposed methods [27-30], is compatible with a 
membranous structure of the chondral layer and provides quantitative data. In this context, it 
is relevant to underline that the minimum strength of integration needed at the time of 
implantation, which should support graft resistance to the shear forces acting in the joint and 
should determine the appropriate post-operative loading regime, has not yet been established 
[9]. On the other hand, the value we obtained at the end of the in vitro culture was up to 10-
fold that provided by acellular fibrin glue, which is currently used in clinical practice for the 
sealing of chondral grafts. Translated to a clinical scenario, this suggests that the developed 
OC grafts, thanks to the presence of newly formed extracellular matrix anchoring the two 
layers, could allow for implementation of less cautious post-operative rehabilitation protocols.  
The influence of certain natural and synthetic subchondral scaffolds on engineered cartilage 
development has been already reported [8,9]. Biphasic grafts made of various biomaterials 
and porcine chondrocytes have been evaluated by Wang et al. [8]. In that study the authors 
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obtained better results with collagen-hydroxyapatite subchondral scaffolds in terms of 
chondral layer quality and macroscopic integration, as compared to those obtained with 
polymeric materials such as poly-L-lactide and poly-D,L-lactide. This motivated the choice 
for the scaffolds in our cell-based graft. The influence of a substrate based on devitalized bone 
on cartilaginous tissue development in OC constructs was recently addressed by Lima et al. in 
a different model (bovine chondrocytes from 1-3 weeks-old calves seeded in agarose gel) [9]. 
In their model they showed a lower quality of the cartilaginous layer of OC grafts including 
that bony substrate, but also in chondral samples co-cultured with their bony substrate. To 
improve these results they proposed to use porous tantalum metal instead of devitalized bone. 
In our OC model, the presence of Tutobone® did not reduce the GAG accumulation of the 
chondral layer, if that was pre-cultured for 3 days. Based on the co-culture experiment (Fig. 
1B), the observed slight reduction in the staining for type II collagen should not be attributed 
to the presence of the Tutobone® material per se, but is likely a result of reduced mass transfer 
due to the presence of an adjacent material, and prompts for future studies possibly 
introducing perfusion-based bioreactor systems to overcome this limit [31].  
Our proposed method for producing osteochondral constructs also has certain limitations: the 
thickness of the chondral layer of the graft (around 1 mm) makes it suitable only for the 
regeneration of cartilage defects in small joints (e.g., ankle) and in none of our groups did we 
manage to duplicate the morphology of the tidemark, even if an upregulation of the BSP gene 
was noticed in the chondrocytes in contact with the bony scaffold. However, an engineered 
OC graft can further develop once implanted in the joint and undergo a remodelling process 
that can even increase tissue thickness and recreate the bone-cartilage interface, as shown by 
Kandel et al [7]. This process could be facilitated by local mechanical loading in the ‘in vivo 
bioreactor’ of the joint, and further emphasizes the need to generate grafts that could tolerate 




The OC grafts engineered according to the described method display several features 
advocating a large potential for clinical implementation, including: (i) a biological bonding of 
the chondral layer with the bony scaffold through the extracellular matrix produced by human 
cells; (ii) a clinically relevant diameter; (iii) a suitable stability allowing easy surgical 
handling and the possibility of insertion into the joint through a recently developed technique 
[32]; and (iv) a versatility in adaptation to different joints, thanks to the use of bony layers 
with appropriate curvatures, quantitatively defined using anatomical data [33]. These results 
suggest that this model, which is based on human cells and biomaterials currently in clinical 
use, could be relatively early introduced in clinical practice and represents a step ahead 
towards the more ambitious engineering of biological substitutes for total joint replacement. 
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